

**Supplemental
Notice of Allowability**

Application No.

10/500,218

Examiner

Taylor Victor Oh

Applicant(s)

HORIUCHI, YOSHIHIRO

Art Unit

1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 1/21/09.
2. ☒ The allowed claim(s) is/are 1-6,8-11,16-17,20, renumbered as claims 1-13.
3. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☒ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|---|
| <ol style="list-style-type: none"> 1. <input type="checkbox"/> Notice of References Cited (PTO-892) 2. <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) 3. <input type="checkbox"/> Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date _____ 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material | <ol style="list-style-type: none"> 5. <input type="checkbox"/> Notice of Informal Patent Application 6. <input checked="" type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date <u>1/21/09</u>. 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment 8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance 9. <input type="checkbox"/> Other _____. |
|--|---|

Supplemental Examiner's Amendment and Reasons of Allowance

The Status of Claims

Claims 1-6,8-11,16-17, and 20 are pending.

Claims 1-6,8-11,16-17, and 20 are allowable.

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with an attorney of record, Amid E. Schmid on 1/21/09 .

2. The application has been amended as follows:

In claim 1, lines 1-2, on page 2 (the amendment dated on 10/24/08), the phrase "-- or a pharmaceutically acceptable salt thereof, which is --" before the term "represented" is removed.

In claim 1, line 16, on page 4 (the amendment dated on 10/24/08), the phrase "-- , or a pharmaceutically acceptable salt thereof-- " is inserted after " (wherein R¹³ and R¹⁴ are the same as defined above)".

In claim 2, lines 1-2, on page 4 (the amendment dated on 10/24/08), the phrase "-- or pharmaceutically acceptable salt thereof --" before the term "of" is removed.

In claim 2, line 3, on page 4 (the amendment dated on 10/24/08), the phrase "-- , or a pharmaceutically acceptable salt thereof-- " is inserted after "C1-3 lower alkyl group".

In claim 3, lines 1-2, on page 4 (the amendment dated on 10/24/08), the phrase “ -- or pharmaceutically acceptable salt thereof --” before the term “ of” is removed.

In claim 3, line 3, on page 4 (the amendment dated on 10/24/08), the phrase “ -- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “C3-5 lower alkyl group”.

In claim 4, lines 1-2, on page 4 (the amendment dated on 10/24/08), the phrase “ -- or pharmaceutically acceptable salt thereof --” before the term “ of” is removed.

In claim 4, line 3, on page 4 (the amendment dated on 10/24/08), the phrase “ -- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “-(CH₂)_m-Y-(CH₂)_q”.

In claim 5, lines 1-2, on page 5 (the amendment dated on 10/24/08), the phrase “ -- or pharmaceutically acceptable salt thereof --” before the term “ of” is removed.

In claim 5, line 3, on page 5 (the amendment dated on 10/24/08), the phrase “ -- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “-(CH₂)_m-Y-(CH₂)_q”.

In claim 6, lines 1-2, on page 5 (the amendment dated on 10/24/08), the phrase “ -- or pharmaceutically acceptable salt thereof--” before the term “ of” is removed.

In claim 6, line 6, on page 5 (the amendment dated on 10/24/08), the phrase “ -- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “ lower cycloalkoxy group”.

In claim 8, lines 1-2, on page 5 (the amendment dated on 10/24/08), the phrase “ -- or pharmaceutically acceptable salt thereof--” before the term “ of” is removed.

In claim 8, line 3, on page 5 (the amendment dated on 10/24/08), the phrase “ -- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “-(CH₂)₂-Y-(CH₂)₂”.

In claim 9, lines 1-2, on page 5 (the amendment dated on 10/24/08), the phrase “ -- or pharmaceutically acceptable salt thereof --” before the term “ of” is removed.

In claim 9, line 3, on page 5 (the amendment dated on 10/24/08), the phrase “ -- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “ methyl group”.

In claim 10, lines 1-2, on page 5 (the amendment dated on 10/24/08), the phrase “ -- or pharmaceutically acceptable salt thereof --” before the term “ of” is removed.

In claim 10, line 8, on page 5 (the amendment dated on 10/24/08), the phrase “ -- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “ methyl group”.

In claim 11, lines 1-2, on page 6 (the amendment dated on 10/24/08), the phrase “ -- or pharmaceutically acceptable salt thereof --” before the term “ of” is removed.

In claim 11, line 2, on page 6 (the amendment dated on 10/24/08), the term “ -- in --” before the terms “ claim 1” is removed.

In claim 11, line 4, on page 6 (the amendment dated on 10/24/08), the phrase “ -- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “C1-4 lower alkoxy group”.

In claim 16, line 2, on page 6 (the amendment dated on 10/24/08), the phrase “ -- a hydroxamic acid compound, or a pharmaceutically acceptable salt thereof --” after the term “ administering” is replaced with the phrase “ the hydroxamic acid compound or pharmaceutically acceptable salt thereof”.

In claim 20, line 2, on page 6 (the amendment dated on 10/24/08), the phrase “ -- a pharmaceutically acceptable salt thereof --” after the terms “ the hydroxamic acid compound ” is replaced with the phrase “pharmaceutically acceptable salt thereof”.

3.. The following is an examiner's statement of reasons for allowance:

- The objection of Claims 1 and 6 has been withdrawn due to the modification of the claims.
- The rejection of Claims 15 and 18 under 35 U.S.C. 112, first paragraph or second paragraph has been withdrawn due to the cancellation of the claims.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.

Any inquiry concerning the communication after allowance such as sending all post-allowance correspondence should be directed to “ Box Issue Fee” or faxed directly to PUBS at 703-305-8755. This will expedite the process of these papers.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Taylor Victor Oh/
Primary Examiner, Art Unit 1625
1/21/09